Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 14/20 | 0.52 |
| ▸ | NPC1 | O15118 | 14/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 12/20 | 0.52 |
| ▸ | CASP3 | P42574 | 3/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 3/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | PRNP | P04156 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946632 | 0.77 | NPC1 (0.52) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL4773008 | 0.77 | NPC1 (0.46) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL242857 | 0.77 | RAB9A (0.47) | RAB9ANPC1SMN1; SMN2TSHRHPGD | |
| SCHEMBL5551673 | 0.73 | NOTUM (0.50) | TSHRALDH1A1NOTUML3MBTL1MAPK1 | |
| SCHEMBL795461 | 0.71 | NPC1 (0.44) | RAB9ANPC1SMN1; SMN2TSHRHPGD | |
| SCHEMBL7756394 | 0.69 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL5552360 | 0.68 | NPC1 (0.42) | RAB9ANPC1SMN1; SMN2TSHRHPGD | |
| SCHEMBL5552349 | 0.67 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL8362955 | 0.67 | NPC1 (0.58) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL28325888 | 0.67 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2CASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304070-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | claimed |
| US-20050101778-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2005-05-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101778-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | RAB9A 1704/4885NPC1 2702/4885SMN1; SMN2 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.